Jeff Jones
Stock Analyst at Oppenheimer
(3.73)
# 958
Out of 5,182 analysts
94
Total ratings
33.72%
Success rate
14.61%
Average return
Main Sectors:
Stocks Rated by Jeff Jones
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ACRS Aclaris Therapeutics | Initiates: Outperform | $10 | $4.22 | +136.97% | 1 | Apr 16, 2026 | |
| ALMS Alumis | Maintains: Outperform | $50 → $55 | $24.02 | +128.98% | 4 | Mar 30, 2026 | |
| PTHS Pelthos Therapeutics | Maintains: Outperform | $60 → $62 | $24.97 | +148.30% | 4 | Mar 20, 2026 | |
| PHAR Pharming Group | Reiterates: Outperform | $42 → $41 | $16.46 | +149.09% | 1 | Mar 13, 2026 | |
| CRVS Corvus Pharmaceuticals | Reiterates: Outperform | $32 → $33 | $15.62 | +111.27% | 7 | Mar 13, 2026 | |
| CRBP Corbus Pharmaceuticals Holdings | Maintains: Outperform | $53 → $57 | $9.82 | +480.45% | 11 | Mar 10, 2026 | |
| AVBP ArriVent BioPharma | Reiterates: Outperform | $44 → $50 | $30.04 | +66.44% | 4 | Mar 6, 2026 | |
| KYMR Kymera Therapeutics | Maintains: Outperform | $67 → $120 | $83.85 | +43.11% | 7 | Dec 9, 2025 | |
| CMMB Chemomab Therapeutics | Maintains: Outperform | $10 → $25 | $1.48 | +1,594.92% | 9 | Aug 27, 2025 | |
| ZURA Zura Bio | Maintains: Outperform | $19 → $17 | $5.30 | +220.75% | 4 | May 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $85 → $86 | $28.79 | +198.71% | 2 | May 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $28 → $18 | $3.62 | +397.24% | 4 | Jan 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $2.56 | - | 5 | Dec 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $22 → $16 | $3.95 | +305.06% | 7 | Nov 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $48 → $45 | $1.21 | +3,619.01% | 6 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $7.09 | - | 4 | Jun 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Perform | n/a | $4.74 | - | 3 | Apr 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $2.26 | - | 2 | May 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $15 | $1.42 | +956.34% | 5 | May 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $1,875 | $2.56 | +73,142.19% | 2 | Mar 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $1,600 → $1,100 | $4.32 | +25,362.96% | 2 | Nov 17, 2022 |
Aclaris Therapeutics
Apr 16, 2026
Initiates: Outperform
Price Target: $10
Current: $4.22
Upside: +136.97%
Alumis
Mar 30, 2026
Maintains: Outperform
Price Target: $50 → $55
Current: $24.02
Upside: +128.98%
Pelthos Therapeutics
Mar 20, 2026
Maintains: Outperform
Price Target: $60 → $62
Current: $24.97
Upside: +148.30%
Pharming Group
Mar 13, 2026
Reiterates: Outperform
Price Target: $42 → $41
Current: $16.46
Upside: +149.09%
Corvus Pharmaceuticals
Mar 13, 2026
Reiterates: Outperform
Price Target: $32 → $33
Current: $15.62
Upside: +111.27%
Corbus Pharmaceuticals Holdings
Mar 10, 2026
Maintains: Outperform
Price Target: $53 → $57
Current: $9.82
Upside: +480.45%
ArriVent BioPharma
Mar 6, 2026
Reiterates: Outperform
Price Target: $44 → $50
Current: $30.04
Upside: +66.44%
Kymera Therapeutics
Dec 9, 2025
Maintains: Outperform
Price Target: $67 → $120
Current: $83.85
Upside: +43.11%
Chemomab Therapeutics
Aug 27, 2025
Maintains: Outperform
Price Target: $10 → $25
Current: $1.48
Upside: +1,594.92%
Zura Bio
May 9, 2025
Maintains: Outperform
Price Target: $19 → $17
Current: $5.30
Upside: +220.75%
May 8, 2025
Maintains: Outperform
Price Target: $85 → $86
Current: $28.79
Upside: +198.71%
Jan 24, 2025
Maintains: Outperform
Price Target: $28 → $18
Current: $3.62
Upside: +397.24%
Dec 11, 2024
Downgrades: Perform
Price Target: n/a
Current: $2.56
Upside: -
Nov 22, 2024
Maintains: Outperform
Price Target: $22 → $16
Current: $3.95
Upside: +305.06%
Aug 8, 2024
Maintains: Outperform
Price Target: $48 → $45
Current: $1.21
Upside: +3,619.01%
Jun 7, 2024
Downgrades: Perform
Price Target: n/a
Current: $7.09
Upside: -
Apr 1, 2024
Reiterates: Perform
Price Target: n/a
Current: $4.74
Upside: -
May 23, 2023
Downgrades: Perform
Price Target: n/a
Current: $2.26
Upside: -
May 11, 2023
Reiterates: Outperform
Price Target: $15
Current: $1.42
Upside: +956.34%
Mar 24, 2023
Reiterates: Outperform
Price Target: $1,875
Current: $2.56
Upside: +73,142.19%
Nov 17, 2022
Maintains: Outperform
Price Target: $1,600 → $1,100
Current: $4.32
Upside: +25,362.96%